Jan Mueller

Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease

A. Warth, W. Stremmel, W. Chamulitrat, 2012, Hepatology.

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

B. Ebert, M. Manz, S. M. Stolz, 2022, Blood advances.

Disruption of CSF-1R signaling inhibits growth of AML with inv(16).

S. Balabanov, M. Manz, P. Valk, 2021, Blood advances.

Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF‐β1/Smad2/3 signalling

W. Stremmel, Jiliang Wang, A. Warth, 2014, British journal of pharmacology.